Scientists at the Ineos Oxford Institute (IOI) have found a new potential combination therapy to combat antimicrobial resistance (AMR) by targeting two key bacterial enzymes involved in resistance. The study, "The Triple Combination of Meropenem, Avibactam, and a Metallo-β-Lactamase Inhibitor Optimizes Antibacterial Coverage Against Different β-Lactamase Producers," has been published in Engineering. Read this story
